Curis assumed with a Buy at H.C. Wainwright

H.C. Wainwright assumed coverage of Curis (CRIS) with a Buy rating and $17 price target Curis is a clinical-stage biopharmaceutical company developing novel therapies for cancer treatment, the analyst tells investors in a research note. The firm says the company’s lead drug candidate, emavusertib, is a potential first-in-class oral, small molecule inhibitor of IRAK4, which mediates signaling downstream of toll-like receptor superfamily. It sees a “promising” early efficacy profile in the lead non-Hodgkin’s lymphoma subtype being evaluated in TakeAim lymphoma.